Literature DB >> 8355194

Selective potentiation by an A1 adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart.

B Amoah-Apraku1, J Xu, J Y Lu, A Pelleg, R F Bruns, L Belardinelli.   

Abstract

The drug (2-amino-4,5-dimethyl-3-thienyl)-[3(trifluoromethyl)-phenyl]methanone (PD 81,723) has been shown to enhance allosterically A1 adenosine receptor binding in brain membranes. The objective of this study was to determine the specificity and selectivity (A1 versus A2) of PD 81,723 as an enhancer of the negative dromotropic effect of exogenous adenosine in guinea pig isolated and in situ hearts. In isolated hearts, PD 81,723 alone produced only a small stimulus to His bundle (S-H) interval prolongation of 1.5 to 4 msec, which was completely reversed by the A1 adenosine receptor antagonist 8-cyclopentyltheophylline and adenosine deaminase. PD 81,723 (5 microM) significantly decreased the EC50 value of adenosine for prolongation of the S-H interval from 6.7 +/- 0.6 to 4.4 +/- 0.5 microM. The potentiation of the negative dromotropic effect of adenosine by PD 81,723 was dose dependent, i.e., 5 and 10 microM PD 81,723 enhanced the maximal S-H interval prolongation caused by 3 microM adenosine by 207% and 609%, respectively. In contrast, the same concentration of PD 81,723 had no effect on either the S-H interval prolongation caused by carbachol or MgCl2 or the coronary vasodilatory effect of adenosine. In in situ hearts, PD (2 mumol/kg i.v.) alone caused only a small but not significant negative dromotropic effect, increasing the atrium to His interval from 58 +/- 2 to 61 +/- 1 msec. However, the same dose of PD 81,723 caused a significant leftward and upward shift of the adenosine dose-response curve for inducing atrium to His bundle interval prolongation and increased the degree of atrioventricular block caused by adenosine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8355194

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.

Authors:  Samita Bhattacharya; Rebecca L Youkey; Kobina Ghartey; Matthew Leonard; Joel Linden; Amy L Tucker
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

2.  The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers.

Authors:  Dylan P Kennedy; Fiona M McRobb; Susan A Leonhardt; Michael Purdy; Heidi Figler; Melissa A Marshall; Mahendra Chordia; Robert Figler; Joel Linden; Ruben Abagyan; Mark Yeager
Journal:  Mol Pharmacol       Date:  2013-11-11       Impact factor: 4.436

Review 3.  Drugs for allosteric sites on receptors.

Authors:  Cody J Wenthur; Patrick R Gentry; Thomas P Mathews; Craig W Lindsley
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-02       Impact factor: 13.820

Review 4.  Allosteric modulation of purine and pyrimidine receptors.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Anikó Göblyös; Adriaan P Ijzerman
Journal:  Adv Pharmacol       Date:  2011

5.  Enhancement of adenosine A1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro.

Authors:  E Leung; L K Walsh; L A Flippin; E J Kim; D A Lazar; C S Seran; E H Wong; R M Eglen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

Review 6.  Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization.

Authors:  Stephen J Hill; Lauren T May; Barrie Kellam; Jeanette Woolard
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

7.  An allosteric modulator of the adenosine A1 receptor improves cardiac function following ischaemia in murine isolated hearts.

Authors:  Anna Butcher; Peter J Scammells; Paul J White; Shane M Devine; Roselyn B Rose'meyer
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.